5 names are moving together; 60% are participating in the current session.
Observed member paths adjusted against SPY. Shading marks the latest observation window.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| PHG | Koninklijke Philips N.V. NY Reg | Healthcare | -0.3% | Most structurally connected |
| IBN | ICICI Bank Limited | Financial Services | +0.9% | Group member |
| VTRS | Viatris Inc. | Healthcare | +0.8% | Group member |
| HDB | HDFC Bank Limited | Financial Services | -0.4% | Group member |
| AMRX | Amneal Pharmaceuticals, Inc. | Healthcare | +1.1% | Group member |
Cohort
5 namesParticipation
60% this sessionObserved history
3 daily buildsThis identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
AMRXcustomer · Not moving with the group now
Filing receipt · JAZZ / AMRX
“Specifically, a wholly owned subsidiary of Hikma launched its AG version of sodium oxybate in January 2023 and Amneal launched its AG version of sodium oxybate in July 2…”
AMRX · customer
AMRXcompetitor · Not moving with the group now
Filing receipt · SPRY / AMRX
“Additionally, the development of new treatment methods for the diseases we are targeting could render our current or future product candidates non-competitive or obsolet…”
AMRX · competitor
VTRSpartner · Not moving with the group now
Filing receipt · TBPH / VTRS
“The stability of revefenacin in both metered dose inhaler and dry powder inhaler (“MDI/DPI”) formulations suggests that revefenacin could also serve as a foundation for…”
VTRS · partner
VTRSsupplier · Not moving with the group now
Filing receipt · LXRX / VTRS
“Lexicon and Viatris have entered into a manufacturing and supply agreement pursuant to which Lexicon will supply the development and commercial requirements of sotaglifl…”
VTRS · supplier
AMRXcompetitor · Not moving with the group now
Filing receipt · LENZ / AMRX
“As VIZZ is marketed for the treatment of presbyopia, we may face competition from a variety of companies developing or marketing other pharmaceutical presbyopia therapie…”
AMRX · competitor